#177 — Psychedelic Science

Episode Summary

Executive Summary: Sam Harris announces Making Sense will move to a subscription model, arguing ad-supported media has damaged culture and that audience support alone is insufficient. He then interviews Roland Griffiths about psychedelic research, covering the history of prohibition, safety and screening, MDMA and classic psychedelics, mystical-type experiences, and the potential therapeutic and ethical significance of these compounds.

Main Topics: Podcast business model change: Harris explains why he is converting the podcast from a supporter-based model to a subscription service, citing the failure of both ad and voluntary support models and the need for a sustainable real media business. History of psychedelic prohibition and research revival: Griffiths describes how psychedelics were pushed out of scientific research after the 1960s, then gradually reintroduced through FDA-approved studies, especially at Johns Hopkins. Safety, screening, and risks: The conversation details major risks: panic, dangerous behavior, and possible psychosis in vulnerable people, plus the need for careful screening, preparation, and supervised settings. MDMA versus classic psychedelics: They distinguish MDMA from psilocybin/LSD/DMT/mescaline, discussing MDMA’s neurotoxicity debate, its empathogenic effects, and its promise for PTSD treatment. Mystical-type experiences and consciousness: Griffiths argues that psychedelics reliably produce experiences of unity, sacredness, noetic insight, and lasting meaning, offering a scientifically tractable route to study consciousness and spirituality. Therapeutic and moral implications: The discussion emphasizes potential benefits for depression, addiction, end-of-life anxiety, and pro-social/ethical transformation, while warning against premature mass use.

Key Arguments: Ad-supported digital media has distorted journalism, politics, privacy, and incentives; a subscription model is more honest and sustainable. Audience support alone has remained stuck in the single digits, making the podcast financially unstable despite strong listener praise. Psychedelic research was suppressed for decades by legal and cultural backlash, creating a major gap in scientific knowledge. Properly screened and supported psychedelic sessions can be conducted with very low serious adverse-event rates in clinical settings. The main dangers of psychedelics are psychological and situational, not acute physical toxicity. People vulnerable to psychotic disorders should be excluded because psychedelics may precipitate or worsen schizophrenia-spectrum illness. Classic psychedelics mainly act on the serotonin-2A receptor and are more similar than different, though onset and duration vary. MDMA is pharmacologically distinct from classic psychedelics and has a real but context-dependent neurotoxicity debate. Psychedelic experiences often resemble classical mystical states, including unity, sacredness, noetic insight, positive mood, timelessness, and ineffability. These experiences can have lasting life significance and may increase gratitude, humility, and pro-social orientation. Naturally occurring versus synthetic psychedelics may not differ meaningfully at the molecular level, though mushroom preparations may contain other psychoactive compounds. Psychedelics may serve as a ‘crash course’ for meditation and consciousness exploration, but meditation remains the more durable practice.

Data Points: Subscriber support rate: single digits - Harris says the percentage of listeners supporting the show has never climbed beyond the single digits. Podcast center funding: $17 million - Johns Hopkins’ Center for Psychedelic and Consciousness Research received philanthropic support to expand its work. Years of psychedelic research at Hopkins: 20 years - Griffiths says his psilocybin program began around 2000 and has continued for two decades. Year of first meditation reintroduction: 1993 - Griffiths says he re-engaged with meditation around 1993. FDA-approved high-dose psychedelic study: 2000 - Griffiths says Hopkins’ approval to give a reasonably high dose of a psychedelic to psychedelic-naive people was granted around 2000. Psychedelic survey sample size: almost 2000 people - Griffiths references a survey of people describing their worst psilocybin experience. Survey risk of putting self/others in danger: 11% - Among respondents describing worst psilocybin experiences, 11% reported putting themselves or others at risk for physical harm. Survey seeking medical help: 3% - A portion of respondents sought medical help after their worst psilocybin experience. Long-term adverse symptoms: 10% - Respondents reported adverse psychological symptoms lasting more than a year. Those long-term sufferers who sought treatment: 8% - Of respondents with long-term symptoms, 8% sought treatment. Duration of mystical-type experiences in follow-up ratings: 80%-90% in top five lifetime experiences - Griffiths says most participants rate the experience among the most meaningful or spiritually significant of their lives. Rated among top five meaningful experiences: about 80%-90% - Participants commonly compare the experience to a first child’s birth or a parent’s death. Psychedelic-naive volunteers studied: healthy volunteers who had never before experienced a psychedelic - Hopkins’ early psilocybin study intentionally avoided prior users to reduce selection bias. MDMA clinical dosing range: 75 mg to 125 mg - Griffiths describes typical therapeutic MDMA doses used in trials. MDMA dosing schedule in MAPS trials: two doses - He notes MAPS protocols often give an initial dose and a booster about an hour later. Proportion of prepared volunteers who can have mystical-type experiences: about 80% - Griffiths says optimized conditions can produce these experiences in a high proportion of participants. Atheism shift after encountering entity: about one third remained atheist - He says self-identified atheists were less likely to remain atheist after entity-like encounters. Years of psychedelic prohibition: decades - The conversation emphasizes the long hiatus in legal human psychedelic research after the 1960s.

Pivotal Quotes: "the support model is broken, probably in principle" — Sam Harris: Harris explains why he is ending the audience-support system for the podcast. "These experiences map on to these naturally occurring mystical type experiences" — Roland Griffiths: Griffiths describes why psychedelics are scientifically valuable for studying consciousness and spirituality. "we're all in this together" — Roland Griffiths: Griffiths links psychedelic unity experiences to ethical and moral implications.

Implications: Listeners will need to subscribe for full episodes, while the conversation highlights psychedelics as a fast-evolving field with major therapeutic promise, real safety constraints, and potential to reshape research on consciousness, meaning, and morality.